

Version 6.0	Revision Date: 16.05.2024		S Number:)297-00021	Date of last issue: 17.04.2024 Date of first issue: 28.01.2016
Section 1	: Identification			
Produ	uct name	:	Cephapirin Form	ulation
Other	Other means of identification		Metricure (A0073 METRICURE BE SUSPENSION (4	NZATHINE CEPHAPIRIN INTRA-UTERINE
Manւ Com	u facturer or supplier's d bany	letai :	il s MSD	
Addre	ess	:	33 Whakatiki Stro Upper Hutt - New	eet - Private Bag 908 v Zealand
Telep	hone	:	0800 800 543	
Emer	gency telephone number	• :	0800 764 766 (08 CHEMCALL)	300 POISON) 0800 243 622 (0800
E-ma	il address	:	EHSDATASTEW	ARD@msd.com
Reco	mmended use of the ch	nem	ical and restriction	ons on use
	mmended use ictions on use	:	Veterinary produ Not applicable	ct
Section 2	: Hazard identification			
	Classification iratory sensitisation	:	Category 1	
	label elements rd pictograms	:		
Signa	al word	:	Danger	
Haza	rd statements	:	H334 May cause difficulties if inhal	allergy or asthma symptoms or breathing ed.
Preca	autionary statements	:	Prevention: P261 Avoid brea P284 Wear respi	hing mist or vapours. ratory protection.

Response:

SAFETY DATA SHEET



Cephapirin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 17.04.2024
6.0	16.05.2024	420297-00021	Date of first issue: 28.01.2016

P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture	:	Mixture
---------------------	---	---------

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cefapirin	21593-23-7	>= 1 -< 10

Section 4: First-aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.
In case of skin contact	:	Wash with water and soap as a precaution. Get medical attention if symptoms occur.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	May cause allergy or asthma symptoms or breathing difficul- ties if inhaled. Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reac- tive airways dysfunction syndrome).
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media :

Water spray Alcohol-resistant foam



Version 6.0	Revision Date: 16.05.2024		0S Number: 0297-00021	Date of last issue: 17.04.2024 Date of first issue: 28.01.2016
medi Spec fighti	ific hazards during fire-	Carbon dioxide (Cu Dry chemical : None known. : Exposure to combu : Carbon oxides		CO2) pustion products may be a hazard to health.
ods Spec	ific extinguishing meth- ial protective equipment efighters	:	 Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to c so. Evacuate area. In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment. 	
Section 6	: Accidental release me	as	ures	
tive e	onal precautions, protec- equipment and emer- y procedures	:	Follow safe handl	tective equipment. ing advice (see section 7) and personal pro- recommendations (see section 8).
Envir	onmental precautions	:	 Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment o barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained. 	
	ods and materials for ainment and cleaning up	:	For large spills, pu ment to keep mat be pumped, store Clean up remainin bent. Local or national u posal of this mate employed in the c mine which regula Sections 13 and 1	t absorbent material. rovide dyking or other appropriate contain- erial from spreading. If dyked material can recovered material in appropriate container. ng materials from spill with suitable absor- regulations may apply to releases and dis- rial, as well as those materials and items leanup of releases. You will need to deter- ations are applicable. 15 of this SDS provide information regarding tional requirements.

Section 7: Handling and storage

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation Advice on safe handling		Use only with adequate ventilation. Avoid breathing mist or vapours.



Cephapirin Formulation

Version 6.0	Revision Date: 16.05.2024	SDS Number: 420297-00021	Date of last issue: 17.04.2024 Date of first issue: 28.01.2016
Hygie	ene measures	 Handle in accorpractice, based sessment Keep contained Already sensitities to asthma, allered should consult tory irritants or Take care to prenvironment. If exposure to a flushing system place. When using do Wash contamined the effective or engineering corporpriate de industrial hygie 	with eyes. ed or repeated contact with skin. ordance with good industrial hygiene and safety d on the results of the workplace exposure as- r tightly closed. sed individuals, and those susceptible rgies, chronic or recurrent respiratory disease, their physician regarding working with respira- sensitisers. revent spills, waste and minimize release to the chemical is likely during typical use, provide eye ns and safety showers close to the working o not eat, drink or smoke. nated clothing before re-use. peration of a facility should include review of ntrols, proper personal protective equipment, gowning and decontamination procedures, ene monitoring, medical surveillance and the
Cond	itions for safe storage	: Keep in proper Keep tightly clo	
Mater	rials to avoid		lance with the particular national regulations. ith the following product types: g agents

Section 8: Exposur	e controls/personal	protection
--------------------	---------------------	------------

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Cefapirin	21593-23-7	TWA	0.4 mg/m3 (OEB 2)	Internal
	Further information	ation: RSEN		
Engineering measures	Use appropriate engineering controls and manu technologies to control airborne concentrations less quick connections). All engineering controls should be implemented design and operated in accordance with GMP p protect products, workers, and the environment Laboratory operations do not require special co		e concentrations (e.g d be implemented by dance with GMP princ d the environment.	g., drip- facility ciples to
Personal protective equipmer	nt			
Respiratory protection :	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the rec-			•

Components with workplace control parameters 0 Val



Version 6.0	Revision Date: 16.05.2024		DS Number: 20297-00021	Date of last issue: 17.04.2024 Date of first issue: 28.01.2016
			ommended guide	lines, use respiratory protection.
	lter type protection	:		ulates and organic vapour type
	aterial	:	Chemical-resista	nt gloves
If the work environment or activ mists or aerosols, wear the app Wear a faceshield or other full f		ses with side shields or goggles. Inment or activity involves dusty conditions, , wear the appropriate goggles. d or other full face protection if there is a st contact to the face with dusts, mists, or		
Skin a	and body protection	:	Work uniform or l	aboratory coat.
Section 9	: Physical and chemic	al p	roperties	
Appe	arance	:	suspension	
Colou	Colour:No data availableOdour:No data available		e	
Odou			e	
Odou	r Threshold	:	: No data available	
pH : No data available		e		
Maltir	na point/freezina point		No data availabl	0

Appearance	:	suspension
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Solubility(ies) Water solubility	:	No data available

SAFETY DATA SHEET



Cephapirin Formulation

Version 6.0	'n	Revision Date: 16.05.2024		S Number: 0297-00021	Date of last issue: 17.04.2024 Date of first issue: 28.01.2016		
oc Ai Di	ctanol/ .uto-igr /ecomp /iscosit	nition temperature	::	No data available No data available No data available No data available	e e		
E	xplosiv	ve properties	:	Not explosive			
Oxidizing properties Molecular weight		:	The substance or mixture is not classified as oxidizing. No data available				
Particle characteristics Particle size		:	No data available				
Sectio	on 10:	Stability and reactiv	ity				
Reactivity Chemical stability Possibility of hazardous reac- tions Conditions to avoid Incompatible materials Hazardous decomposition products			Stable under nor Can react with st None known. Oxidizing agents	rong oxidizing agents.			

Section 11: Toxicological information

Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
Acute toxicity		

Acute toxicity

Not classified based on available information.

Components:

Cefapirin:		
Acute oral toxicity	:	LD50 (Mouse): 26,000 mg/kg
Acute toxicity (other routes of administration)	:	LD50 (Mouse): > 7,600 mg/kg Application Route: Intraperitoneal
		LD50 (Rat): 7,800 mg/kg Application Route: Intraperitoneal



Version 6.0	Revision Date: 16.05.2024		9S Number: 0297-00021	Date of last issue: 17.04.2024 Date of first issue: 28.01.2016			
-	corrosion/irritation lassified based on ava	ailable	information.				
	ous eye damage/eye i lassified based on ava						
Resp	iratory or skin sensi	tisatio	'n				
•	Skin sensitisation Not classified based on available information.						
-	iratory sensitisation cause allergy or asthm		ptoms or breath	ning difficulties if inhaled.			
Com	ponents:						
Cefaj Asses	pirin: ssment	:	Probability or e humans	evidence of high respiratory sensitisation rate in			
Chro	nic toxicity						
	n cell mutagenicity lassified based on ava	ailable	information.				
Com	ponents:						
Cefa	pirin:						
Geno	toxicity in vitro	:	Test Type: Ba Result: negativ	cterial reverse mutation assay (AMES) /e			
	i nogenicity lassified based on ava	ailable	information.				
-	Reproductive toxicity Not classified based on available information.						
Com	ponents:						
Cefa	pirin:						
Effect	ts on fertility	:	Species: Rat Application Ro	tility/early embryonic development ute: Intraperitoneal injection L: > 500 mg/kg body weight ects on fertility			
Effect ment	ts on foetal develop-	:	Species: Rat Application Ro	bryo-foetal development ute: Intraperitoneal injection I Toxicity: LOAEL: > 200 mg/kg body weight			



Version	Revision Date:	SDS Number:	Date of last issue: 17.04.2024
6.0	16.05.2024	420297-00021	Date of first issue: 28.01.2016

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Cefapirin: Species LOAEL Application Route Target Organs Remarks	: : :	Rat >= 200 mg/kg Intraperitoneal Blood anemia
Species LOAEL Application Route Exposure time Target Organs	:	Dog 20 mg/kg Oral 4 Months Gastrointestinal tract
Species LOAEL Application Route Exposure time Target Organs Remarks	:	Dog 100 mg/kg Intramuscular 10 Months Blood, Gastrointestinal tract anemia

:

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Cefapirin:

Ingestion

Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea, vaginitis, colitis, anorexia, Rash, anaphylaxis

Section 12: Ecological information

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

No data available



ersion .0	Revision Date: 16.05.2024	SDS Number: 420297-00021	Date of last issue: 17.04.2024 Date of first issue: 28.01.2016	
Mobi	lity in soil			
No da	ata available			
Othe	r adverse effects			
No de	ata available			

Waste from residues	:	Do not dispose of waste into sewer.
		Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste han-
		dling site for recycling or disposal.
		If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG UN number Proper shipping name Class Subsidiary risk Packing group Labels Environmentally hazardous	Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable no
IATA-DGR UN/ID No. Proper shipping name Class Subsidiary risk Packing group Labels Packing instruction (cargo aircraft) Packing instruction (passen- ger aircraft)	Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable
IMDG-Code UN number Proper shipping name Class Subsidiary risk Packing group Labels EmS Code Marine pollutant	Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.



Version 6.0	Revision Date: 16.05.2024	SDS Number: 420297-00021	Date of last issue: 17.04.2024 Date of first issue: 28.01.2016
Natior	nal Regulations		

NZS 5433	
UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Hazchem Code	: Not applicable

Special precautions for user

Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number

HSR100759 Veterinary Medicines Non dispersive Open System Application Group Standard

Tolerable Exposure Limits (TEL)

Not applicable

Environmental Exposure Limits (EEL)

Not applicable

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

Section 16: Other information

Revision Date	:	16.05.2024
Further information Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

SAFETY DATA SHEET



Cephapirin Formulation

Version	Revision Date:	SDS Number:
6.0	16.05.2024	420297-0002

r: 1 Date of last issue: 17.04.2024 Date of first issue: 28.01.2016

Date format dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN